• Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @ InternationalDrugMart.com.
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Ranbaxy gets nod for Alzheimer’s drug

      Posted Atlivemint.com

      Ranbaxy Laboratories Ltd, India’s largest pharmaceutical company by revenue, has received the US drug regulator’s nod to launch its generic version of Pfizer Inc. and Eisai Co. Ltd’s Alzheimer’s drug Aricept (Donepezil hydrochloride), two people familiar with the development said.

      Analysts expect the company to launch the drug on Monday.

      Aricept has estimated sales of about $1.6 billion (`7,312 crore) in the US. Its patent expired on 25 November. In September, the US Food and Drug Administration (FDA) informed Ranbaxy that it had first-to-file status for Aricept in the US. This gives Ranbaxy 180 days of marketing exclusivity for the drug.

      While Arun Sawhney, managing director of Ranbaxy, had said in a recent conference call that the company was confident of monetizing the opportunity, FDA’s final approval for Ranbaxy to launch the drug was uncertain. A Ranbaxy official said the company had received approval.

      “We expect the company to launch the product on Monday,” a Mumbai-based analyst said, requesting anonymity.

      “This is good news for Ranbaxy,” said another analyst with a Mumbai-based brokerage, who also did not want to be named. “We expect it to make approximately $300 million in revenues from the sale of the drug in the exclusivity period. This also gives confidence to investors that the company may be able to get approvals for future first-to-file drugs in the light of FDA and DoJ (department of justice) issues.”

      US-based Mutual Pharma got approval to sell its generic version of Aricept orally disintegrating tablets in 2009 for the treatment of dementia. These, however, are different from Ranbaxy’s version. Ranbaxy will also face competition from Greenstone Pharma, the generic pharmaceutical subsidiary of Pfizer Inc, which will launch the authorised generic of Aricept.

      Ranbaxy faces an import alert in the US for 30 products and a warning on two of its plants—Paonta Sahib in Himachal Pradesh and Dewas in Madhya Pradesh. FDA has also halted all application reviews from Ranbaxy’s Paonta Sahib plant. Ranbaxy had previously failed to get approval for the generic version of Flomax, which it planned to launch in March.

      According to the first analyst, Ranbaxy will manufacture and distribute Aricept from its US facility ,Ohm Laboratories.

      Nov 30, 2010


      Share this Article!

    Back to top^